Cargando…

Cefepime-Resistant Pseudomonas aeruginosa

Detalles Bibliográficos
Autores principales:	Akhabue, Ehimare, Synnestvedt, Marie, Weiner, Mark G., Bilker, Warren B., Lautenbach, Ebbing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320237/ https://www.ncbi.nlm.nih.gov/pubmed/21749765 http://dx.doi.org/10.3201/eid1706.100358

Ejemplares similares

Synergistic Effects of Gentamicin, Cefepime, and Ciprofloxacin on Biofilm of Pseudomonas aeruginosa
por: Usman, Muhammad, et al.
Publicado: (2023)

1063. ARGONAUT-V: Susceptibility of Multidrug-Resistant (MDR) Pseudomonas aeruginosa to Cefepime-Taniborbactam
por: Mack, Andrew R, et al.
Publicado: (2021)

Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study
por: Su, Ting-Yi, et al.
Publicado: (2017)

Use of a Precision Antibiotic Therapy (PAT) Prediction Model to Identify Multidrug-Resistant (MDR) Enterobacteriaceae
por: Varga, Alexandra, et al.
Publicado: (2017)

BIChromET: A Chromogenic Culture Medium for Detection of Piperacillin/Tazobactam and Cefepime Resistance in Pseudomonas aeruginosa
por: Ortiz de la Rosa, José Manuel, et al.
Publicado: (2023)

1800. Clinical Impact of Real-Time Predictive Model to Facilitate Antibiotic Prescribing in Gram-Negative Bacteremia
por: Hamilton, Keith W, et al.
Publicado: (2018)

In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model
por: Abdelraouf, Kamilia, et al.
Publicado: (2023)

Draft Genome Sequences of Cefepime-Resistant and -Susceptible Escherichia coli Strains and Imipenem-Resistant and -Susceptible Pseudomonas aeruginosa Strains
por: Batchelder, Kendra, et al.
Publicado: (2021)

Comparison of efficiency of intravitreal ceftazidime and intravitreal cefepime in the treatment of experimental Pseudomonas aeruginosa endophthalmitis
por: Deniz, Nurettin, et al.
Publicado: (2013)

Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate
por: Pan, Xiaolei, et al.
Publicado: (2022)

Preparation, characterization and in vitro antimicrobial activity of liposomal ceftazidime and cefepime against Pseudomonas aeruginosa strains
por: Torres, Ieda Maria Sapateiro, et al.
Publicado: (2012)

Poor Clinical Outcomes Associated with Community-Onset Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae Urinary Tract Infections
por: Anesi, Judith, et al.
Publicado: (2017)

In vitro Reducing Effect of Cloxacillin on Minimum Inhibitory Concentrations to Imipenem, Meropenem, Ceftazidime, and Cefepime in Carbapenem-resistant Pseudomonas aeruginosa Isolates
por: Pahlavanzadeh, Farahnaz, et al.
Publicado: (2020)

Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime/ceftazidime susceptibility profiles
por: Laohavaleeson, Somvadee, et al.
Publicado: (2008)

The Impact of Reported β-Lactam Allergy on Clinical Outcomes and Antibiotic Use Among Solid Organ Transplant Recipients
por: Zhang, Helen L, et al.
Publicado: (2022)

The role of extended-spectrum cephalosporin-resistance in recurrent community-onset Enterobacteriaceae urinary tract infections: a retrospective cohort study
por: Anesi, Judith A., et al.
Publicado: (2019)

1168. Role of Extended-Spectrum Cephalosporin-Resistance in Recurrent Enterobacteriaceae Urinary Tract Infections
por: Anesi, Judith, et al.
Publicado: (2018)

2150. In Vitro Activity of Cefepime-Taniborbactam and Comparators Against Genotypically Characterized Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) from the United States, 2018-2021
por: Wise, Mark G, et al.
Publicado: (2023)

203. Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Pseudomonas aeruginosa from a Global 2018-2020 Surveillance Collection
por: Hackel, Meredith, et al.
Publicado: (2021)

High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli
por: Rattanaumpawan, Pinyo, et al.
Publicado: (2017)

Combination of Epicatechin 3-Gallate from Euphorbia hirta and Cefepime Promotes Potential Synergistic Eradication Action against Resistant Clinical Isolate of Pseudomonas aeruginosa
por: Perumal, Shanmugapriya, et al.
Publicado: (2018)

725. WCK 5222 (Cefepime/Zidebactam): An In Vitro Assessment of Activity Compared with Current Dual-Antibiotic Options Against Multidrug-Resistant Pseudomonas aeruginosa
por: Mullane, Elias M, et al.
Publicado: (2019)

A Clinical Prediction Tool for Extended-Spectrum Cephalosporin Resistance in Community-Onset Enterobacterales Urinary Tract Infection
por: Weinstein, Erica J, et al.
Publicado: (2019)

1961. A Randomized Controlled Trial of the Effect of Accelerated Copper Textiles on Healthcare-Associated Infections and Multidrug-Resistant Organisms: The “Investigating Microbial Pathogen Activity of Copper Textiles” (IMPACT) Study
por: Lautenbach, Ebbing, et al.
Publicado: (2018)

Resistance of Pseudomonas Aeruginosa
por: Graevenitz, Alexander Von
Publicado: (1977)

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
por: Hamrick, Jodie C., et al.
Publicado: (2020)

Cefepime: Cefepime-induced encephalopathy: case report
Publicado: (2022)

Fluoroquinolone-resistant Escherichia coli Carriage in Long-Term Care Facility
por: Maslow, Joel N., et al.
Publicado: (2005)

1588. Clinical Prediction Tool for Extended-Spectrum Β Lactamase-Producing Enterobacteriaceae as the Etiology of Bacteremia in Solid Organ Transplant Recipients
por: Wang, Rebecca, et al.
Publicado: (2018)

675. Efficacy of Human-Simulated Bronchopulmonary Exposures of Cefepime and Zidebactam (WCK 5222) Against Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PSA) in a Neutropenic Murine Pneumonia Model
por: Kidd, James M, et al.
Publicado: (2019)

Pseudomonas Aeruginosa: Resistance to the Max
por: Poole, Keith
Publicado: (2011)

The multifactorial resistance of Pseudomonas aeruginosa
por: Meliani, Amina
Publicado: (2020)

The prevalence of Pseudomonas aeruginosa and multidrug resistant Pseudomonas aeruginosa in healthy captive ophidian
por: Sala, Andrea, et al.
Publicado: (2019)

Disparate Cardiovascular Hospitalization Trends Among Young and Middle‐Aged Adults Within and Across Race and Ethnicity Groups in Four States in the United States
por: Akhabue, Ehimare, et al.
Publicado: (2022)

279 Prevalence and Epidemiology of Mupirocin Resistance Among Those Colonized with Methicillin-resistant Staphylococcus aureus in the Community
por: Cluzet, Valerie C., et al.
Publicado: (2014)

1286. Taniborbactam Inhibits Cefepime-Hydrolyzing Variants of Pseudomonas-derived Cephalosporinase (PDC)
por: Mack, Andrew R, et al.
Publicado: (2021)

Mechanism of resistance to phagocytosis and pulmonary persistence in mucoid Pseudomonas aeruginosa
por: Rowe, Warren J., et al.
Publicado: (2023)

520. Development of Cefepime-taniborbactam MIC Antimicrobial Susceptibility Test (AST) for Enterobacterales and Pseudomonas aeruginosa on MicroScan Dried Gram-negative MIC Panels
por: Fernandez, Enrique J, et al.
Publicado: (2022)

Association of State Medicaid Expansion With Rate of Uninsured Hospitalizations for Major Cardiovascular Events, 2009-2014
por: Akhabue, Ehimare, et al.
Publicado: (2018)

In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5b887hpoeh73aha51hphdhcn5n